Camlin Fine Sciences Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
CAMLINFINE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.5 pts less than Nifty Microcap 250 and 3.0 pts less than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The Board approved unaudited standalone and consolidated financial results for Q1 FY26 (quarter ended June 30, 2025). Consolidated revenue from operations grew about 11% year-on-year to Rs. 423.55 crore (from Rs. 380.85 crore in Q1 FY25), while standalone revenue rose about 5% to Rs. 191.44 crore (from Rs. 181.91 crore). Despite top-line growth, the company reported losses – standalone loss after tax of Rs. 10.68 crore (vs Rs. 13.68 crore in Q1 FY25) and consolidated loss after tax of Rs. 10.68 crore (vs a small profit of Rs. 0.11 crore in Q1 FY25). Loss from continuing operations on a consolidated basis narrowed to Rs. 4.25 crore from Rs. 7.05 crore. The Board also approved the re-appointment of Mr. Joseph Conrad D'Souza as Independent Director for a second 5-year term, the appointment of an Alternate Director, and gave interim additional charge of HR & Admin to the CFO following a senior executive's resignation. A Rs. 224.68 crore rights issue completed in January 2025 has bolstered equity capital.
Mixed picture for shareholders – revenue growth is encouraging but profitability remains weak with losses continuing into Q1 FY26. The narrowing of operating losses and completion of the rights issue provide some support, but persistent losses and reclassification of two overseas facilities as discontinued operations signal continued cleanup of underperforming businesses, which may keep the stock under pressure until profitability returns.